Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed adult patients = 65 years old with a cytopathologically confirmed diagnosis of high-risk AML~* = 20% bone marrow blasts via bone marrow aspiration or biopsy~* The patient has not yet been treated for AML~* 1º or 2º AML patients with high-risk category features~* ECOG PS = 2~* Renal function and liver function limits.~Exclusion Criteria:~* Patient with a 'favorable' or 'better-risk' cytogenetic profile = t(15;17); t(8;21); or inv(16) or t(16;16)~* Patient has clinical symptoms suggestive of CNS leukemia and/or CSF findings for CNS leukemia~* Prior treatment with deacetylase inhibitors (DACi) including, panobinostat~* Impaired cardiac function~* Female patient who is pregnant or breast feeding~* Male patient who is not willing to use a barrier method of contraception~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Panobinostat (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).